Technical Analysis for AZN - Astrazeneca PLC

Grade Last Price % Change Price Change
A 66.21 2.59% 1.67
AZN closed up 2.59 percent on Friday, May 20, 2022, on approximately normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Gapped Up Strength 0.00%
Outside Day Range Expansion 2.59%
Fell Below 20 DMA Bearish 4.56%
Fell Below 50 DMA Bearish 4.56%
Gapped Down Weakness 4.56%
Crossed Above 20 DMA Bullish 0.87%
Crossed Above 50 DMA Bullish 0.87%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 17 hours ago
50 DMA Resistance about 18 hours ago
Up 2% about 20 hours ago
Up 1 ATR about 20 hours ago
Rose Above 20 DMA about 20 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Astrazeneca PLC Description

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. Its principal products include Atacand for hypertension and heart failure; Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure, and angina; Nexium for acid reflux; Synagis for RSV, a respiratory infection in infants; Seroquel IR for schizophrenia and bipolar disorders; and Seroquel XR for schizophrenia, bipolar disorder, and major depressive disorders. The company principal products also comprise Zoladex for prostate and breast cancer; Pulmicort for asthma and chronic obstructive pulmonary diseases; and Symbicort for asthma and chronic obstructive pulmonary diseases. In addition, it has 84 pipeline projects, which include 71 projects in various clinical phases of development. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc. to develop and commercialize monoclonal antibodies; Ironwood Pharmaceuticals, Inc to co-develop and co-commercialize linaclotide in China; BIND Therapeutics, Inc. to develop and commercialize cancer nanomedicine; and WuXi AppTec to develop and commercialize MEDI5117, a biologic for autoimmune and inflammatory diseases. It also has a strategic alliance with Isis Pharmaceuticals, Inc. for the discovery and development of novel generation antisense therapeutics; and a strategic collaboration with FibroGen, Inc. to develop and commercialize FG-4592, a compound for the treatment of anemia associated with chronic kidney disease and end-stage renal disease. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Cancer Nasdaq 100 Acid Drugs Antibodies IBD 50 Inflammation Breast Cancer Monoclonal Antibodies Neuroscience Gastrointestinal Infection Hypertension Psychoactive Drugs Inflammatory Diseases Kidney Disease Heart Failure Schizophrenia Coronavirus Asthma Pulmonary Disease Chronic Obstructive Pulmonary Disease Major Depressive Disorder Respiratory Diseases Cholesterol Chronic Kidney Disease Primary Care Anemia Depressive Disorder Renal Disease End Stage Renal Disease Stage Renal Disease Autoimmune And Inflammatory Disease Pulmonology Bipolar Disorder Chronic Condition Angina Nanomedicine Respiratory Infection Inflammation Diseases Linaclotide

Is AZN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 71.7
52 Week Low 53.635
Average Volume 7,042,737
200-Day Moving Average 60.37
50-Day Moving Average 65.67
20-Day Moving Average 64.85
10-Day Moving Average 63.64
Average True Range 1.63
RSI 53.92
ADX 17.43
+DI 31.47
-DI 30.34
Chandelier Exit (Long, 3 ATRs) 64.19
Chandelier Exit (Short, 3 ATRs) 65.24
Upper Bollinger Bands 68.33
Lower Bollinger Band 61.36
Percent B (%b) 0.7
BandWidth 10.74
MACD Line -0.44
MACD Signal Line -0.55
MACD Histogram 0.1074
Fundamentals Value
Market Cap 173.78 Billion
Num Shares 2.62 Billion
EPS 0.95
Price-to-Earnings (P/E) Ratio 69.69
Price-to-Sales 5.36
Price-to-Book 11.36
PEG Ratio 1.22
Dividend 1.40
Dividend Yield 2.11%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 68.28
Resistance 3 (R3) 68.10 67.23 67.94
Resistance 2 (R2) 67.23 66.70 67.32 67.82
Resistance 1 (R1) 66.72 66.38 66.98 66.90 67.70
Pivot Point 65.85 65.85 65.98 65.94 65.85
Support 1 (S1) 65.34 65.32 65.60 65.52 64.72
Support 2 (S2) 64.47 65.00 64.56 64.60
Support 3 (S3) 63.96 64.47 64.49
Support 4 (S4) 64.14